KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Resmed (RMD) Equity Average (2016 - 2025)

Historic Equity Average for Resmed (RMD) over the last 16 years, with Q4 2025 value amounting to $6.2 billion.

  • Resmed's Equity Average rose 1908.6% to $6.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $6.2 billion, marking a year-over-year increase of 1908.6%. This contributed to the annual value of $5.4 billion for FY2025, which is 2043.55% up from last year.
  • Resmed's Equity Average amounted to $6.2 billion in Q4 2025, which was up 1908.6% from $6.0 billion recorded in Q3 2025.
  • Resmed's 5-year Equity Average high stood at $6.2 billion for Q4 2025, and its period low was $2.8 billion during Q1 2021.
  • Over the past 5 years, Resmed's median Equity Average value was $4.1 billion (recorded in 2023), while the average stood at $4.2 billion.
  • Over the last 5 years, Resmed's Equity Average had its largest YoY gain of 2347.26% in 2021, and its largest YoY loss of 1132.86% in 2021.
  • Resmed's Equity Average (Quarter) stood at $3.1 billion in 2021, then grew by 16.19% to $3.6 billion in 2022, then rose by 21.77% to $4.4 billion in 2023, then increased by 19.65% to $5.2 billion in 2024, then increased by 19.09% to $6.2 billion in 2025.
  • Its Equity Average was $6.2 billion in Q4 2025, compared to $6.0 billion in Q3 2025 and $5.8 billion in Q2 2025.